Competition Agency Warns India Pharma Against Industry Practices
This article was originally published in PharmAsia News
The Competition Commission of India is looking into anticompetitive behavior in the nation's pharmaceutical industry. The CCI has asked industry representatives to discuss the way they set prices and market and sell their goods at the retail level. Current practices do not reflect the competitive spirit, the CCI says. Discussions are considered a prelude to official action against anticompetitive practices. (Click here for more
You may also be interested in...
Novartis seems to have accepted the fact that the indication granted for Piqray in the EU means there is little scope for the advanced breast cancer drug to be used in markets such as the UK.
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
Latest EU company news: Sanofi grows OTC portfolio in France and Italy with ColdZyme; Germany's WindStar Medical gets UK owners; and France's Ipsen continues to fell effects of COVID-19 on sales.